Others titles

  • Psychiatric Hospital Compare Data by Facility
  • Inpatient Hospital Quality Measures
  • CMS Quality Measures Data
  • IPQRF Program Quality Measures
  • Inpatient Psychiatric Hospital Facility Quality Measures
  • Inpatient Psychiatric Hospital Facility Quality Reporting Program

Keywords

  • Quality Reporting Programs
  • Quality Reporting Payments
  • Quality of Care Information
  • Eligible Psychiatric Hospitals
  • Psychiatric Hospital
  • Psychiatric Services
  • CMS Hospital Compare
  • Psychiatric Hospital Facilities

Inpatient Psychiatric Hospital Facility Quality Measures by Facility

This dataset includes Psychiatric facilities that are eligible for the Inpatient Psychiatric Facility Quality Reporting (IPFQR) program are required to meet all program requirements, otherwise their Medicare payments may be reduced. It contains facility-wise data for the hospitals in United States for several inpatient psychiatric facility quality measures.

Log in to download
Complexity

Get The Data

For getting access to data download links please read and accept the end-user license agreement.
Your Data License
  • Research
    Non-Commercial, Share-Alike, Attribution Free Forever
  • Commercial
    Commercial Use, Remix & Adapt, White Label Log in to download

John Snow Labs Standard End User License Agreement

Last updated:January 20, 2021

This Standard End User License Agreement (“EULA”) applies to customers of John Snow Labs Inc. (as defined below), using any product of John Snow Labs Inc. on John Snow Labs Marketplace as defined below (hereinafter referred to “you”) and John Snow Labs Inc., a Delaware corporation (“John Snow Labs”, “we” or “us”).

By downloading, installing, and/or using (as applicable) any Product of John Snow Labs (as defined below), you automatically agree to be bound by, and use our Products in compliance with, this EULA. This EULA, together with additional terms and conditions and/or policies referenced herein or located on https://www.johnsnowlabs.com and/or conveyed to you by John Snow Labs, is a legally binding contract between you and John Snow Labs.

PLEASE READ THIS EULA CAREFULLY BEFORE PURCHASING, INSTALLING OR USING OUR PRODUCTS MADE AVAILABLE ON JOHN SNOW LABS MARKETPLACE.

We may make changes to this EULA from time to time. When we do so, we will revise the “last updated” date given above. The then-current version of this EULA will supersede all earlier versions. You agree that your continued use of our Products after such changes have been published to our EULA will constitute your acceptance of such revised EULA.

Definitions

“John Snow Labs Data Library” means a data library located at https://www.johnsnowlabs.com;

“Products” means products and services of John Snow Labs that you download and use from listings in John Snow Labs Data Library;

Important Notice

By installing and using our Products, you acknowledge that the use of the Products can be subject to the restrictions and controls imposed by United States export regulations.

You represent and warrant that you do not intend to use the Products for any purpose prohibited by United States export regulations, including, without limitation, terrorism, cyber-attacks, cyber-crimes, money-laundering, industrial espionage, or nuclear, chemical or biological weapons proliferation. Further, you represent and warrant that you are not listed as a denied party on any list governing United States exports.

Eligibility

Our Products can be used by an individual, business or other legal entity, or both. If you are entering into this EULA, or using the Products, on behalf of a company or other legal entity, you represent that you have the authority to bind such entity to this EULA, in which case “you” shall refer to such entity.

In the event you have entered into a separate written agreement with John Snow Labs regarding the Products that contemplates terms that are inconsistent with this EULA, the written agreement shall control and this EULA will not apply to you to the extent inconsistent with such written agreement, or, if such written agreement is contemplated to be in lieu of this EULA, then this EULA shall not apply at all.

Your Access and Use

Subject to your compliance with this EULA, as well as any other applicable policies, John Snow Labs grants you non-exclusive, non-transferable, license to install, access to, modify, and use of, the Products worldwide (subject to applicable export laws) during the term of this EULA (as described below) solely for research, private study and personal use of Products.

This license is personal to you, and you may not resell our Products, permit other users access to our Products through your account. Your right to use our Products is limited by all terms and conditions set forth in this EULA.

Except for your pre-existing rights and this license granted to you, we and our licensors retain all rights, titles and interests in and to our Products, all related intellectual property rights, including trademarks (whether registered or pending), domain and business names. Our Products are protected by applicable intellectual property laws, including United States copyright law and international treaties.

Except for the foregoing license, you have no other rights in the Products and you may not modify, edit, copy, reproduce, create derivative works of, reverse engineer, alter, enhance or in any way exploit the Products in any manner. If you breach any of this EULA, the above license will terminate automatically.

You will be deemed to have taken any action that you permit, assist or facilitate any person or entity to take related to this EULA, your content or use of the Products. You are responsible for end users’ use of your content and the Products. You will ensure that all end users comply with your obligations under this EULA and that the terms of your agreement with each end user are consistent with this EULA. If you become aware of any violation of your obligations under this EULA caused by an end user, you will immediately suspend access to your content and the Products by such end user. We do not provide any support or services to end users unless we have a separate agreement with you or an end user obligating us to provide such support or services.

Restrictions

You will access or use our Products solely via John Snow Labs Data Library.

Except as otherwise explicitly provided in this EULA or as may be expressly permitted by applicable law, you will not, and will not permit or authorize any third party to:

  1. reproduce, modify, translate, enhance, decompile, disassemble, reverse engineer or create derivative works of any of our Products or its technological features or measures;
  2. rent, lease, sell, resell, loan, distribute, or sublicense access to any of our Products;
  3. circumvent or disable any security or technological features or measures of our Products;
  4. use our intellectual property rights without our express prior written authorization;
  5. use our Products for more than one trial period, unless the trial period is extended by John Snow Labs’ prior written permit;
  6. use our Products with an intent to build a competitive product or service, or copy or substantially copy any ideas, features, functions, organization, structure, application program interface, graphics, or user interface of the Products;
  7. store, copy, modify, distribute, or resell any of the information; audio, visual, and audiovisual works, or other content made available on our Products (collectively, “Content”) or compile or collect any Content as part of a database or other work;
  8. use any automated tool (e.g., robots, spiders) to access or use our Products, or to store, copy, modify, distribute, or resell any Content;
  9. circumvent or disable any rights management, usage rules, or other security features of our Products;
  10. use our Products in a manner that overburdens, or that threatens the integrity, performance, or availability of, our Products; or
  11. remove, alter, or obscure any proprietary notices (including copyright and trademark notices) on any portion of our Products or any Content.

Fees and Taxes

Your use of the Products is subject to our fees. All fees are given on our website https://www.johnsnowlabs.com. Except as set forth in this EULA, the fees are non-refundable. We are entitled to revise our fees from time to time.

The fees exclude any federal, state or local taxes, VAT, GST, or similar taxes. You are responsible for identification and payment of all taxes as required by applicable law.

Term and Termination

This EULA will become effective as of the date of your order of Products and shall be in effect until terminated.

John Snow Labs may suspend or terminate your right to use our Products, if you or your end user’s use of the Products:

  1. is in breach of this EULA;
  2. poses a security risk to our Products;
  3. could adversely impact our systems, the Products or other customers;
  4. could subject us, our affiliates, or any third party to liability; or
  5. could be fraudulent.

We may also suspend or terminate your right to use our Products, if you fail to perform your payment obligations, or you have ceased to operate in the ordinary course, made an assignment for the benefit of creditors or similar disposition of your assets, or become the subject of any bankruptcy, reorganization, liquidation, dissolution or similar proceeding.

We may also suspend or terminate your right to use our Products without any reason upon a relevant 30 days’ written notice to you and will refund the unused fees pre-paid by you for access to the Products for the affected time period (if any). Where your access is suspended or terminated by the breach of this EULA or applicable laws, John Snow Labs will will not provide, or be liable for, any refund.

You will cease use of the Products during any period of suspension, or upon termination of this EULA.

All provisions which by their nature are intended to survive termination shall survive termination of this EULA.

Support

If applicable to your Product, John Snow Labs will provide you with the support services. If you use a trial access, support services are excluded. Under this EULA, our support services exclude any installation, training, maintenance services (including any error corrections, bug fixes, or new releases), technical assistance, consulting services, or other services of any kind. Such services are provided at John Snow Labs’ discretion.

From time to time John Snow Labs can perform updates to our software. If available, such updates may include bug fixes, new features and/or enhancements. You are solely responsible for deploying such updates at your own risk and liability.

Access to our Products

We do not provide you with the equipment to access our Products. You are responsible for all fees charged by third parties related to your access and use of our Products (e.g., charges by Internet service providers).

You are responsible for monitoring your use of the Products, including payment of all fees and/or taxes related to such access and use. You agree that John Snow Labs is permitted to request and you hereby consent to provide John Snow Labs information related to your use of the Products for auditing purposes.

You also certify that you are legally permitted to use the Products, and take full responsibility for the selection and use of the Products. This EULA is void where prohibited by law, and the right to use the Products is revoked in such jurisdictions. John Snow Labs makes no claim that the Products may be lawfully used outside of the United States. If you use the Products from outside of the United States, you do so at your own risk and you are responsible for compliance with the laws of jurisdiction.

Privacy Policy

We may collect, store and receive personal and other information about you through our Products. Our collection and use of this information is governed by our Privacy Policy available at https://www.JohnSnowLabs.com/privacy/ which may be amended from time to time.

Links and Third Party Content

Our Products may display, or contain links to, third party products, services, and websites. Any opinions, advice, statements, services, offers, or other information that constitutes part of the content expressed, authored, or made available by other users or other third parties, or which is accessible through or may be located using our Products (collectively, “Third Party Content”) are those of the respective authors or producers and not of us or our shareholders, directors, officers, employees, agents, or representatives.

We do not control Third Party Content and do not guarantee the accuracy, integrity or quality of such Third Party Content. We are not responsible for the performance of, we do not endorse, and we are not responsible or liable for, any Third Party Content or any information or materials advertised in any Third Party Content. By using our Products, you may be exposed to content that is offensive, indecent, or objectionable. We are not responsible or liable, directly or indirectly, for any damage or loss caused to you by your use of or reliance on any goods, services, or information available on or through any third party service or Third Party Content. It is your responsibility to evaluate the information, opinion, advice, or other content available on and through our Products.

Proprietary Rights

John Snow Labs will not obtain any rights under this EULA from you (or your licensors) to your content.

The Products, including software, is and remains the exclusive property of John Snow Labs and its licensors. Except for the access and use rights expressly set forth in this EULA, no license or other rights in or to the Products or John Snow Labs trademark(s) and other intellectual property rights therein, are granted to you, and all such licenses and rights are expressly reserved. You will not remove, alter, or obscure any proprietary notices (including copyright and trademark notices) on any portion of our Products or any Content.

Trademarks

“John Snow Labs,” the John Snow Labs logo, and any other product, business or service name or slogan, whether registered or pending, displayed on our Products are trademarks of John Snow Labs, Inc. or its suppliers or licensors, and may not be copied, imitated or used, in whole or in part, without the prior written permission of John Snow Labs or the applicable trademark holder. You may not use any metatags or any other “hidden text” utilizing “John Snow Labs” or any other name, trademark or product, business or service name of John Snow Labs without our prior written permission. In addition, the look and feel of our Products, including all page headers, custom graphics, button icons and scripts, is the service mark, trademark and/or trade dress of John Snow Labs and may not be copied, imitated or used, in whole or in part, without our prior written permission. All other trademarks, pending trademarks, registered trademarks, product names and company names or logos mentioned in our Products are the property of John Snow Labs Inc. and/or their respective owners. Reference to any products, services, processes or other information, by trade name, trademark, manufacturer, supplier, or otherwise does not constitute or imply endorsement, sponsorship, or recommendation thereof by us.

Disclaimer of Warranties

YOUR USE OF THE PRODUCTS IS AT YOUR SOLE RISK. THE PRODUCTS AND CONTENT EACH ARE PROVIDED ON AN “AS IS” AND “AS AVAILABLE” BASIS. WE AND OUR SUPPLIERS AND LICENSORS EXPRESSLY DISCLAIM ALL WARRANTIES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, AND NON-INFRINGEMENT. WE DO NOT GUARANTEE THE ACCURACY, COMPLETENESS, OR USEFULNESS OF THE PRODUCTS OR ANY CONTENT, AND YOU RELY ON THE PRODUCTS AND CONTENT AT YOUR OWN RISK. ANY MATERIAL THAT YOU ACCESS OR OBTAIN THROUGH OUR PRODUCTS IS DONE AT YOUR OWN DISCRETION AND RISK AND YOU WILL BE SOLELY RESPONSIBLE FOR ANY DAMAGE TO YOUR COMPUTER OR LOSS OF DATA THAT RESULTS FROM THE DOWNLOAD OF ANY MATERIAL THROUGH OUR PRODUCTS. NO ADVICE OR INFORMATION, WHETHER ORAL OR WRITTEN, OBTAINED BY YOU FROM US OR THROUGH OR FROM OUR PRODUCTS WILL CREATE ANY WARRANTY NOT EXPRESSLY STATED IN THIS EULA. SOME STATES MAY PROHIBIT A DISCLAIMER OF WARRANTIES AND YOU MAY HAVE OTHER RIGHTS THAT VARY FROM STATE TO STATE.

Limitation of Liability

WE AND OUR SUPPLIERS AND LICENSORS WILL NOT BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL, OR EXEMPLARY DAMAGES, INCLUDING BUT NOT LIMITED TO, DAMAGES FOR LOSS OF PROFITS, GOODWILL, USE, DATA, OR OTHER INTANGIBLE LOSSES (EVEN IF WE HAVE BEEN ADVISED OF THE POSSIBILITY OF THESE DAMAGES), RESULTING FROM YOUR USE OF OUR PRODUCTS AND CONTENT. UNDER NO CIRCUMSTANCES WILL THE TOTAL LIABILITY OF US AND OUR SUPPLIERS AND LICENSORS OF ALL KINDS ARISING OUT OF OR RELATED TO YOUR USE OF THE PRODUCTS AND CONTENT (INCLUDING BUT NOT LIMITED TO WARRANTY CLAIMS), REGARDLESS OF THE FORUM AND REGARDLESS OF WHETHER ANY ACTION OR CLAIM IS BASED ON CONTRACT, TORT, OR OTHERWISE, EXCEED THE AMOUNTS, IF ANY, THAT YOU HAVE PAID FOR YOUR USE OF THE PRODUCTS AND CONTENT. BECAUSE SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF LIABILITY FOR CONSEQUENTIAL OR INCIDENTAL DAMAGES, THE ABOVE LIMITATION MAY NOT APPLY TO YOU.

Indemnity

To the full extent permitted by applicable law, you shall defend, indemnify and hold harmless John Snow Labs, its affiliates and its licensors, and each of their respective employees, officers, directors, and representatives from and against any claims, damages, losses, liabilities, costs, and expenses (including reasonable attorney’s fees) arising out of or relating to any third party claim concerning: (a) your use of the Products; (b) breach of this EULA or violation of applicable law by you; (c) any content or the combination of such content with other software, content or processes, including any claim involving alleged infringement or misappropriation of third-party rights by such content or combination; or (d) breach of any obligation or duty you owe to a third party.

Legal Notices

Enforcement of this EULA will be governed by the laws of the State of Delaware, excluding its conflict and choice of law principles. The exclusive jurisdiction and venue for any claims arising out of or related to this EULA or your use of the Products will lie in the state and federal courts located in Sussex County, within the State of Delaware, and you irrevocably agree to submit to the jurisdiction of such courts. Our failure to enforce any right or provision in this EULA will not constitute a waiver of such right or provision unless acknowledged and agreed by us in writing. In the event that a court of competent jurisdiction finds any provision of this EULA to be illegal, invalid, or unenforceable, the remaining provisions will remain in full force and effect.

Notifications

We may use your contact information to notify you if we have any legitimate interest or if we need to notify you on any important information related to your use of Products. We will not send you newsletters unless you expressly consented to such notifications.

Contacting Us

If you have any questions or concerns about our Products or this EULA, you may contact us by email at support@JohnSnowLabs.com.

Description

The Inpatient Psychiatric Hospital Facility Quality Reporting (IPFQR) program is being developed as mandated by section 1886(s)(4) of the Social Security Act (SSA), as added and amended by Sections 3401(f) and 10322(a) of the Affordable Care Act (Pub.L. 111-148).
The IPFQR program is a pay-for-reporting program intended to equip consumers with quality of care information to make more informed decisions about healthcare options. It is also intended to encourage hospitals and clinicians to improve the quality of inpatient care provided to beneficiaries by, first, ensuring that providers are aware of and reporting on best practices for their respective facilities and type of care. Because this is a pay-for-reporting program, facilities will be subject to payment reduction for non-participation. Eligible Psychiatric hospitals that do not participate in the IPFQR program in a fiscal year will receive a 2.0 percentage point reduction to their annual update to their standard federal rate for that year. The reduction is noncumulative across payment years.

The IPFQR program requires facilities to submit data for specific inpatient psychiatric clinical process measures. These quality measures will be announced no later than October 1, 2012. To meet the IPFQR program requirement, Inpatient Psychiatric Facilities (IPFs) will be required to submit all quality measures in the form, manner, and time as specified by the Secretary, to the Centers for Medicare & Medicaid Services (CMS), beginning with Fiscal Year (FY) 2014 payment determination year and subsequent fiscal years. Participating IPFs must comply with the program requirements, which will be set forth through rule-making, including public reporting of the measure rates.

About this Dataset

Data Info

Date Created

2014-01-28

Last Modified

2023-07-05

Version

2023-07-05

Update Frequency

Quarterly

Temporal Coverage

N/A

Spatial Coverage

United States

Source

John Snow Labs; Centers for Medicare & Medicaid Services;

Source License URL

Source License Requirements

N/A

Source Citation

N/A

Keywords

Quality Reporting Programs, Quality Reporting Payments, Quality of Care Information, Eligible Psychiatric Hospitals, Psychiatric Hospital, Psychiatric Services, CMS Hospital Compare, Psychiatric Hospital Facilities

Other Titles

Psychiatric Hospital Compare Data by Facility, Inpatient Hospital Quality Measures, CMS Quality Measures Data, IPQRF Program Quality Measures, Inpatient Psychiatric Hospital Facility Quality Measures, Inpatient Psychiatric Hospital Facility Quality Reporting Program

Data Fields

Name Description Type Constraints
Provider_NumberCMS certification number (CCN). Identification number of the hospital within the CMS dataset.integerlevel : Nominal
Hospital_NameName of the hospital (also referred to as the provider)string-
AddressMain street address information of the hospitalstring-
CityMailing city. The city in the main street address of the hospital.string-
State_AbbreviationTwo-letter state abbreviation in the mailing address of the hospital. This includes information on hospitals in:string-
ZIP_Code5 digit postal zip code in the mailing address of the hospital.integerlevel : Nominal
CountyMailing county of the hospital.string-
HBIPS2_Measure_DescriptionDescription of Hospital Based Inpatient Psychiatric Services Core Measure Set. HBIPS2 is described as Hours of Physical Restraint Use. Total hours all patients spent in physical restraint as a proportion of total inpatient hours.string-
HBIPS2_Overall_Rate_Per_1000Indicates the overall rate per 1000 for Hospital Based Inpatient Psychiatric Services (HBIP2) Measure.numberlevel : Ratio
HBIPS2_Overall_NumeratorIndicates the overall Numerator value for Hospital Based Inpatient Psychiatric Services (HBIP2) Measure.numberlevel : Ratio
HBIPS2_Overall_DenominatorIndicates the overall Denominator value for Hospital Based Inpatient Psychiatric Services (HBIPS2) Measure.integerlevel : Ratio
HBIPS2_Overall_FootnoteFootnote Values for Overall Hospital Based Inpatient Psychiatric Services (HBIPS2) Measure. Footnote describes an additional piece of information given separately for the compiled data.string-
HBIPS3_Measure_DescriptionDescription of Hospital Based Inpatient Psychiatric Services Core Measure Set. HBIPS3 is described as Hours of Seclusion Use. Total hours all patients spent in seclusion as a proportion of total inpatient hours.string-
HBIPS3_Overall_Rate_Per_1000Indicates the overall rate per 1000 for Hospital Based Inpatient Psychiatric Services (HBIPS3) Measure.numberlevel : Ratio
HBIPS3_Overall_NumeratorIndicates the overall Numerator value for Hospital Based Inpatient Psychiatric Services (HBIPS3) Measure.numberlevel : Ratio
HBIPS3_Overall_DenominatorIndicates the overall Denominator value for Hospital Based Inpatient Psychiatric Services (HBIPS3) Measure.integerlevel : Ratio
HBIPS3_Overall_FootnoteFootnote Values for Overall Hospital Based Inpatient Psychiatric Services (HBIPS3) Measure. Footnote describes an additional piece of information given separately for the compiled data.string-
HBIPS5_Measure_DescriptionDescription of Hospital Based Inpatient Psychiatric Services Core Measure Set. HBIPS5 is described as Patients discharged on multiple antipsychotic medications with appropriate justification. Percent of patients discharged on multiple antipsychotic medications with appropriate justification as a proportion of patients discharged on two or more antipsychotic medications. Appropriate justifications are limited to augmentation of clozapine, tapering to monotherapy, and history of at least three failed trials of monotherapy.string-
HBIPS5_Overall_Percent_of_TotalIndicates the overall percentage for Hospital Based Inpatient Psychiatric Services (HBIPS5) Measure.numberlevel : Ratio
HBIPS5_Overall_DenominatorIndicates the overall Denominator value for Hospital Based Inpatient Psychiatric Services (HBIPS5) Measure.integerlevel : Ratio
HBIPS5_Overall_FootnoteFootnote Values for Overall Hospital Based Inpatient Psychiatric Services (HBIPS5) Measure. Footnote describes an additional piece of information given separately for the compiled data.string-
SMD_Measure_DescriptionDescription of Screening for Screening for Metabolic Disorders (SMD) Measure.string-
SMD_PercentIndicates the overall percentage for Screening for Metabolic Disorders (SMD) Measure.integerlevel : Ratio
SMD_DenominatorIndicates the overall Denominator value of Screening for Metabolic Disorders (SMD) Measure.integerlevel : Ratio
SMD_FootnoteIndicates the footnote value of Screening for Metabolic Disorders (SMD) Measure. Footnote describes an additional piece of information given separately for the compiled data.string-
SUB2_2a_Measure_DescriptionDescription of Substance Use Treatment Measure. Substance2 is described as Alcohol Use Brief Intervention Provided or Offered.string-
SUB2_PercentIndicates the overall percentage for Substance2 Measure.numberlevel : Ratio
SUB2_DenominatorIndicates the overall Denominator value for Substance2 Measure.integerlevel : Ratio
SUB2_FootnoteFootnote Values for Substance2 Measure. Footnote describes an additional piece of information given separately for the compiled data.string-
SUB2a_PercentIndicates the overall percentage for Substance2a Measure.numberlevel : Ratio
SUB2a_DenominatorIndicates the overall Denominator value for Substance2a Measure.integerlevel : Ratio
SUB2a_FootnoteFootnote Values for Substance2a Measure. Footnote describes an additional piece of information given separately for the compiled data.string-
SUB3_3a_Measure_DescriptionDescription of National-wise Substance Use Treatment Measure. SUB3 3a is described as use of Alcohol and other Drug Use Disorder Treatment Provided or Offered at Discharge.string-
SUB3_PercentIndicates the overall percentage for SUB3 Measure.integerlevel : Ratio
SUB3_DenominatorIndicates the overall Denominator value for SUB3 Measure.integerlevel : Ratio
SUB3_FootnoteIndicates the footnote Values for Substance3 Measure. Footnote describes an additional piece of information given separately for the compiled data.string-
SUB3a_PercentIndicates the overall percentage for SUB3a Measure.integerlevel : Ratio
SUB3a_DenominatorIndicates the overall Denominator value for SUB3a Measure.integerlevel : Ratio
SUB3a_FootnoteIndicates the footnote Values for Substance3a Measure. Footnote describes an additional piece of information given separately for the compiled data.string-
TOB2_2a_Measure_DescriptionDescription of Substance Use Treatment Measure. Tobacco2 is described as Tobacco Use Treatment during the hospital stay.string-
TOB2_PercentIndicates the overall percentage for Tobacco2 Measure.numberlevel : Ratio
TOB2_DenominatorIndicates the overall Denominator value for Tobacco2 Measure.integerlevel : Ratio
TOB2_FootnoteFootnote Values for Tobacco2 Measure. Footnote describes an additional piece of information given separately for the compiled data.string-
TOB2a_PercentIndicates the overall percentage for Tobacco2a Measure.numberlevel : Ratio
TOB2a_DenominatorIndicates the overall Denominator value for Tobacco2a Measure.integerlevel : Ratio
TOB2a_FootnoteFootnote Values for Tobacco2a Measure. Footnote describes an additional piece of information given separately for the compiled data.string-
TOB3_3a_Measure_DescriptionDescription of Substance Use Treatment Measure. It is described as Tobacco Use Treatment Provided or Offered at Discharge.string-
TOB3_PercentIndicates the overall percentage for Tobacco3 Measure.numberlevel : Ratio
TOB3_DenominatorIndicates the overall Denominator value for Tobacco3 Measure.integerlevel : Ratio
TOB3_FootnoteFootnote Values for Tobacco3 Measure. Footnote describes an additional piece of information given separately for the compiled data.string-
TOB3a_PercentIndicates the overall percentage for Tobacco3a Measure.numberlevel : Ratio
TOB3a_DenominatorIndicates the overall Denominator value for Tobacco3a Measure.integerlevel : Ratio
TOB3a_FootnoteFootnote Values for Tobacco3a Measure. Footnote describes an additional piece of information given separately for the compiled data.string-
TR1_Measure_DescriptionDescription of Transition record with specified elements received by discharged patients (TR1).string-
TR1_PercentIndicates the percentage of Transition Record with specified elements (TR1) Measure.integerlevel : Ratio
TR1_DenominatorIndicates the overall Denominator value for Transition Record with specified elements (TR1) Measure.integerlevel : Ratio
TR1_FootnoteFootnote Values for Transition Record with specified elements (TR1) Measure. Footnote describes an additional piece of information given separately for the compiled data.string-
TR2_Measure_DescriptionDescription of Timely Transmission of transition record (TR2) Measure.string-
TR2_PercentIndicates the percentage of Timely Transmission of transition record (TR2) Measure.integerlevel : Ratio
TR2_DenominatorIndicates the overall Denominator value for Timely Transmission of transition record (TR2) Measure.integerlevel : Ratio
TR2_FootnoteFootnote Values for Timely Transmission of transition record (TR2) Measure. Footnote describes an additional piece of information given separately for the compiled data.string-
TR2_Start_DateThe first day of TR2 data measures was collected. The date format is YYYY-MM-DD.date-
TR2_End_DateThe last day of TR2 data measures was collected. The date format is YYYY-MM-DD.date-
FUH_Measure_DescriptionDescription of Follow-Up after Hospitalization (FUH) Measure. FUH for Mental Illness measures the percentage of discharged patients age 6 years or older who had an outpatient visit, an intensive outpatient encounter, or a partial hospitalization with a mental health practitioner, within 7 days and 30 days of discharge. CMS will calculate these measures based on Medicare claims data.string-
FUH30_PercentIndicates the percent for Follow-up after Hospitalization (FUH) for Mental Illness of 30-Days.numberlevel : Ratio
FUH30_DenominatorIndicates the overall Denominator value for Follow-up after Hospitalization (FUH) Measure within 30 Days of discharge.integerlevel : Ratio
FUH30_FootnoteFootnote Values for Follow-Up After Hospitalization (FUH) Measure within 30 Days of discharge. Footnote describes an additional piece of information given separately for the compiled data.integerlevel : Nominal
FUH7_PercentIndicates the percent for Follow-up after Hospitalization (FUH) for Mental Illness of 7-Days.numberlevel : Ratio
FUH7_DenominatorIndicates the overall Denominator value for Follow-up after Hospitalization (FUH) Measure within 30 Days of discharge.integerlevel : Ratio
FUH7_FootnoteFootnote Values for Follow-Up After Hospitalization (FUH) Measure within 30 Days of discharge. Footnote describes an additional piece of information given separately for the compiled data.integerlevel : Nominal
FUH_Measure_Start_DateThe first day of FUH data measures was collected. The date format is YYYY-MM-DD.date-
FUH_Measure_End_DateThe last day of FUH data measures was collected. The date format is YYYY-MM-DD.date-
MedCont_Measure_DescriptionIt is described as Medication Continuation Following Inpatient Psychiatric Discharge.string-
MedCont_PercentIndicates the overall percentage for MedCon Measure.numberlevel : Ratio
MedCont_DenominatorIndicates the overall Denominator value for Medication Continuation Following Inpatient Psychiatric Discharge.integerlevel : Ratio
MedCont_Footnoteintegerlevel : Nominal
MedCont_Measure_Start_DateThe first day the data regarding MedCont measures was collected. The date format is YYYY-MM-DD.date-
MedCont_Measure_End_DateThe last day the data regarding MedCont measures was collected. The date format is YYYY-MM-DD.date-
READM30_IPF_Measure_DescriptionDescription of patients readmitted to any hospital within 30 days of discharge from the inpatient psychiatric facility (READM-30-IPF).string-
READM30_IPF_CategoryIndicates the category of patients readmitted to any hospital within 30 days of discharge from the inpatient psychiatric facility (READM-30-IPF).string-
READM30_IPF_DenominatorIndicates the overall Denominator value for patients readmitted to any hospital within 30 days of discharge from the inpatient psychiatric facility (READM-30-IPF).integerlevel : Ratio
READM30_IPF_RateIndicates the rate for patients readmitted to any hospital within 30 days of discharge from the inpatient psychiatric facility (READM-30-IPF).numberlevel : Ratio
READM30_IPF_Lower_EstimateIndicates the lower estimate value for patients readmitted to any hospital within 30 days of discharge from the inpatient psychiatric facility (READM-30-IPF).numberlevel : Ratio
READM30_IPF_Higher_EstimateIndicates the higher estimate value for patients readmitted to any hospital within 30 days of discharge from the inpatient psychiatric facility (READM-30-IPF).numberlevel : Ratio
READM30_IPF_FootnoteFootnote Values for patients readmitted to any hospital within 30 days of discharge from the inpatient psychiatric facility (READM-30-IPF). Footnote describes an additional piece of information given separately for the compiled data.integerlevel : Nominal
READM30_IPF_Start_DateThe first day the data regarding READM30 IPF Measure was collected. The date format is YYYY-MM-DD.date-
READM30_IPF_End_DateThe last day the data regarding READM30 IPF Measure was collected. The date format is YYYY-MM-DD.date-
IMM2_Measure_DescriptionIndicates the description of Influenza Immunization2 Measure.string-
IMM2_PercentIndicates the overall percentage for Influenza Immunization2 Measure.numberlevel : Ratio
IMM2_DenominatorIndicates the overall Denominator value for Influenza Immunization2 Measure.integerlevel : Ratio
IMM2_FootnoteFootnote Values for Influenza Immunization2 Measure. Footnote describes an additional piece of information given separately for the compiled data.integerlevel : Nominal
Flu_Season_Start_DateThe first day of the Flu Season data measures was collected. The date format is YYYY-MM-DD.date-
Flu_Season_End_DateThe last day of the Flu Season data measures was collected. The date format is YYYY-MM-DD.date-
IPFQR_HCP_COVID19_Measure_DescriptionIt describes inpatient psychiatric hospital facility quality measures percentage of healthcare personnel who completed COVID-19 primary vaccination series (IPFQR- HCP COVID-19).string-
IPFQR_HCP_COVID19_PercentIndicates the overall percentage for IPFQR HCP COVID19 Measure.numberlevel : Ratio
IPFQR_HCP_COVID19_DenominatorIndicates the overall Denominator value for IPFQR HCP COVID19 Measure.integerlevel : Ratio
IPFQR_HCP_COVID19_FootnoteFootnote Values for IPFQR HCP COVID19 Measure. Footnote describes an additional piece of information given separately for the compiled data.integerlevel : Nominal
IPFQR_HCP_COVID19_Start_DateThe first day the data regarding IPFQR HCP COVID19 Measure was collected. The date format is YYYY-MM-DD.date-
IPFQR_HCP_COVID19_End_DateThe last day the data regarding IPFQR HCP COVID19 Measure was collected. The date format is YYYY-MM-DD.date-

Data Preview

Provider NumberHospital NameAddressCityState AbbreviationZIP CodeCountyHBIPS2 Measure DescriptionHBIPS2 Overall Rate Per 1000HBIPS2 Overall NumeratorHBIPS2 Overall DenominatorHBIPS2 Overall FootnoteHBIPS3 Measure DescriptionHBIPS3 Overall Rate Per 1000HBIPS3 Overall NumeratorHBIPS3 Overall DenominatorHBIPS3 Overall FootnoteHBIPS5 Measure DescriptionHBIPS5 Overall Percent of TotalHBIPS5 Overall DenominatorHBIPS5 Overall FootnoteSMD Measure DescriptionSMD PercentSMD DenominatorSMD FootnoteSUB2 2a Measure DescriptionSUB2 PercentSUB2 DenominatorSUB2 FootnoteSUB2a PercentSUB2a DenominatorSUB2a FootnoteSUB3 3a Measure DescriptionSUB3 PercentSUB3 DenominatorSUB3 FootnoteSUB3a PercentSUB3a DenominatorSUB3a FootnoteTOB2 2a Measure DescriptionTOB2 PercentTOB2 DenominatorTOB2 FootnoteTOB2a PercentTOB2a DenominatorTOB2a FootnoteTOB3 3a Measure DescriptionTOB3 PercentTOB3 DenominatorTOB3 FootnoteTOB3a PercentTOB3a DenominatorTOB3a FootnoteTR1 Measure DescriptionTR1 PercentTR1 DenominatorTR1 FootnoteTR2 Measure DescriptionTR2 PercentTR2 DenominatorTR2 FootnoteTR2 Start DateTR2 End DateFUH Measure DescriptionFUH30 PercentFUH30 DenominatorFUH30 FootnoteFUH7 PercentFUH7 DenominatorFUH7 FootnoteFUH Measure Start DateFUH Measure End DateMedCont Measure DescriptionMedCont PercentMedCont DenominatorMedCont FootnoteMedCont Measure Start DateMedCont Measure End DateREADM30 IPF Measure DescriptionREADM30 IPF CategoryREADM30 IPF DenominatorREADM30 IPF RateREADM30 IPF Lower EstimateREADM30 IPF Higher EstimateREADM30 IPF FootnoteREADM30 IPF Start DateREADM30 IPF End DateIMM2 Measure DescriptionIMM2 PercentIMM2 DenominatorIMM2 FootnoteFlu Season Start DateFlu Season End DateIPFQR HCP COVID19 Measure DescriptionIPFQR HCP COVID19 PercentIPFQR HCP COVID19 DenominatorIPFQR HCP COVID19 FootnoteIPFQR HCP COVID19 Start DateIPFQR HCP COVID19 End Date
10007MIZELL MEMORIAL HOSPITAL702 N MAIN STOPPAL36467COVINGTONHours of physical-restraint use0.00.02100Hours of seclusion use0.00.02100Patients discharged on multiple antipsychotic medications with appropriate justification100.023.0Screening for metabolic disorders (SMD)100104Alcohol use brief intervention provided or offered76.017.076.017.0Alcohol and other drug use disorder treatment provided or offered at discharge100.013.0100.013.0Tobacco use treatment provided or offered100.043.065.043.0Tobacco use treatment provided or offered at discharge100.043.065.043.0Transition record with specified elements received by discharged patients (TR1)100166Timely transmission of transition record (TR2)1001662021-01-012021-12-31Percent of patients receiving follow-up care within 30 days (FUH-30) or within 7 days (FUH-7) after hospitalization for mental illness1.01.02020-07-012021-06-30Medication Continuation Following Inpatient Psychiatric Discharge1.02019-07-012021-06-30Patients readmitted to any hospital within 30 days of discharge from the inpatient psychiatric facility (READM-30-IPF)No Different than the National Rate9621.416.228.32019-07-012021-06-30Influenza immunization (IPFQR-IMM-2)74882021-10-012022-03-31Percentage of healthcare personnel who completed COVID-19 primary vaccination series (IPFQR-HCP COVID-19)58.633.02022-07-012022-09-30
10008CRENSHAW COMMUNITY HOSPITAL101 HOSPITAL CIRCLELUVERNEAL36049CRENSHAWHours of physical-restraint use0.1511.913282Hours of seclusion use0.1612.473282Patients discharged on multiple antipsychotic medications with appropriate justification100.0144.0Screening for metabolic disorders (SMD)92352Alcohol use brief intervention provided or offered38.082.029.079.0Alcohol and other drug use disorder treatment provided or offered at discharge1.0310.00.0310.0Tobacco use treatment provided or offered98.0256.01.0256.0Tobacco use treatment provided or offered at discharge97.0234.00.0234.0Transition record with specified elements received by discharged patients (TR1)100352Timely transmission of transition record (TR2)1003522021-01-012021-12-31Percent of patients receiving follow-up care within 30 days (FUH-30) or within 7 days (FUH-7) after hospitalization for mental illness58.817.017.617.02020-07-012021-06-30Medication Continuation Following Inpatient Psychiatric Discharge1.02019-07-012021-06-30Patients readmitted to any hospital within 30 days of discharge from the inpatient psychiatric facility (READM-30-IPF)No Different than the National Rate6017.312.423.42019-07-012021-06-30Influenza immunization (IPFQR-IMM-2)901882021-10-012022-03-31Percentage of healthcare personnel who completed COVID-19 primary vaccination series (IPFQR-HCP COVID-19)74.642.02022-07-012022-09-30
10011ST. VINCENT'S EAST50 MEDICAL PARK EAST DRIVEBIRMINGHAMAL35235JEFFERSONHours of physical-restraint use2.0669.413912Hours of seclusion use0.2479.5913912Patients discharged on multiple antipsychotic medications with appropriate justification1.0Screening for metabolic disorders (SMD)3188Alcohol use brief intervention provided or offered52.027.056.025.0Alcohol and other drug use disorder treatment provided or offered at discharge29.028.018.028.0Tobacco use treatment provided or offered0.092.00.062.0Tobacco use treatment provided or offered at discharge0.051.00.051.0Transition record with specified elements received by discharged patients (TR1)48305Timely transmission of transition record (TR2)483052021-01-012021-12-31Percent of patients receiving follow-up care within 30 days (FUH-30) or within 7 days (FUH-7) after hospitalization for mental illness42.775.032.075.02020-07-012021-06-30Medication Continuation Following Inpatient Psychiatric Discharge72.5138.02019-07-012021-06-30Patients readmitted to any hospital within 30 days of discharge from the inpatient psychiatric facility (READM-30-IPF)No Different than the National Rate25921.818.126.12019-07-012021-06-30Influenza immunization (IPFQR-IMM-2)851192021-10-012022-03-31Percentage of healthcare personnel who completed COVID-19 primary vaccination series (IPFQR-HCP COVID-19)95.530.02022-07-012022-09-30
10012DEKALB REGIONAL MEDICAL CENTER200 MED CENTER DRIVEFORT PAYNEAL35968DE KALBHours of physical-restraint use0.00.03617Hours of seclusion use0.00.03617Patients discharged on multiple antipsychotic medications with appropriate justification1.0Screening for metabolic disorders (SMD)100161Alcohol use brief intervention provided or offered1.01.0Alcohol and other drug use disorder treatment provided or offered at discharge1.01.0Tobacco use treatment provided or offered91.022.071.021.0Tobacco use treatment provided or offered at discharge1.01.0Transition record with specified elements received by discharged patients (TR1)99184Timely transmission of transition record (TR2)981842021-01-012021-12-31Percent of patients receiving follow-up care within 30 days (FUH-30) or within 7 days (FUH-7) after hospitalization for mental illness1.01.02020-07-012021-06-30Medication Continuation Following Inpatient Psychiatric Discharge1.02019-07-012021-06-30Patients readmitted to any hospital within 30 days of discharge from the inpatient psychiatric facility (READM-30-IPF)No Different than the National Rate13719.514.625.12019-07-012021-06-30Influenza immunization (IPFQR-IMM-2)87872021-10-012022-03-31Percentage of healthcare personnel who completed COVID-19 primary vaccination series (IPFQR-HCP COVID-19)5.02022-07-012022-09-30
10016SHELBY BAPTIST MEDICAL CENTER1000 FIRST STREET NORTHALABASTERAL35007SHELBYHours of physical-restraint use0.00.013776Hours of seclusion use0.00.013776Patients discharged on multiple antipsychotic medications with appropriate justification61.041.0Screening for metabolic disorders (SMD)95445Alcohol use brief intervention provided or offered86.042.086.042.0Alcohol and other drug use disorder treatment provided or offered at discharge79.0112.079.0112.0Tobacco use treatment provided or offered94.0157.085.0157.0Tobacco use treatment provided or offered at discharge43.0145.043.0145.0Transition record with specified elements received by discharged patients (TR1)83623Timely transmission of transition record (TR2)826232021-01-012021-12-31Percent of patients receiving follow-up care within 30 days (FUH-30) or within 7 days (FUH-7) after hospitalization for mental illness50.042.021.442.02020-07-012021-06-30Medication Continuation Following Inpatient Psychiatric Discharge1.02019-07-012021-06-30Patients readmitted to any hospital within 30 days of discharge from the inpatient psychiatric facility (READM-30-IPF)No Different than the National Rate14219.214.824.42019-07-012021-06-30Influenza immunization (IPFQR-IMM-2)993012021-10-012022-03-31Percentage of healthcare personnel who completed COVID-19 primary vaccination series (IPFQR-HCP COVID-19)87.958.02022-07-012022-09-30
10021DALE MEDICAL CENTER126 HOSPITAL AVEOZARKAL36360DALEHours of physical-restraint use0.00.0252Hours of seclusion use0.00.0252Patients discharged on multiple antipsychotic medications with appropriate justification1.0Screening for metabolic disorders (SMD)8228Alcohol use brief intervention provided or offered1.01.0Alcohol and other drug use disorder treatment provided or offered at discharge1.01.0Tobacco use treatment provided or offered1.01.0Tobacco use treatment provided or offered at discharge1.01.0Transition record with specified elements received by discharged patients (TR1)034Timely transmission of transition record (TR2)0342021-01-012021-12-31Percent of patients receiving follow-up care within 30 days (FUH-30) or within 7 days (FUH-7) after hospitalization for mental illness45.511.00.011.02020-07-012021-06-30Medication Continuation Following Inpatient Psychiatric Discharge1.02019-07-012021-06-30Patients readmitted to any hospital within 30 days of discharge from the inpatient psychiatric facility (READM-30-IPF)No Different than the National Rate6220.814.928.12019-07-012021-06-30Influenza immunization (IPFQR-IMM-2)100112021-10-012022-03-31Percentage of healthcare personnel who completed COVID-19 primary vaccination series (IPFQR-HCP COVID-19)79.560.02022-07-012022-09-30
10023BAPTIST MEDICAL CENTER SOUTH2105 EAST SOUTH BOULEVARDMONTGOMERYAL36116MONTGOMERYHours of physical-restraint use0.037.2512053Hours of seclusion use0.88254.6312053Patients discharged on multiple antipsychotic medications with appropriate justification93.028.0Screening for metabolic disorders (SMD)86359Alcohol use brief intervention provided or offered65.079.065.063.0Alcohol and other drug use disorder treatment provided or offered at discharge69.0141.063.0141.0Tobacco use treatment provided or offered57.0255.058.0187.0Tobacco use treatment provided or offered at discharge27.0169.08.0169.0Transition record with specified elements received by discharged patients (TR1)86648Timely transmission of transition record (TR2)656482021-01-012021-12-31Percent of patients receiving follow-up care within 30 days (FUH-30) or within 7 days (FUH-7) after hospitalization for mental illness34.097.012.497.02020-07-012021-06-30Medication Continuation Following Inpatient Psychiatric Discharge70.5149.02019-07-012021-06-30Patients readmitted to any hospital within 30 days of discharge from the inpatient psychiatric facility (READM-30-IPF)No Different than the National Rate21717.614.021.92019-07-012021-06-30Influenza immunization (IPFQR-IMM-2)733062021-10-012022-03-31Percentage of healthcare personnel who completed COVID-19 primary vaccination series (IPFQR-HCP COVID-19)94.9125.02022-07-012022-09-30
10033UNIVERSITY OF ALABAMA HOSPITAL619 SOUTH 19TH STREETBIRMINGHAMAL35233JEFFERSONHours of physical-restraint use0.01.3435992Hours of seclusion use0.015.1435992Patients discharged on multiple antipsychotic medications with appropriate justification100.015.0Screening for metabolic disorders (SMD)86313Alcohol use brief intervention provided or offered99.0280.0100.0278.0Alcohol and other drug use disorder treatment provided or offered at discharge99.0266.098.0266.0Tobacco use treatment provided or offered84.0217.01.0217.0Tobacco use treatment provided or offered at discharge82.0197.01.0197.0Transition record with specified elements received by discharged patients (TR1)94717Timely transmission of transition record (TR2)607172021-01-012021-12-31Percent of patients receiving follow-up care within 30 days (FUH-30) or within 7 days (FUH-7) after hospitalization for mental illness27.687.013.887.02020-07-012021-06-30Medication Continuation Following Inpatient Psychiatric Discharge62.493.02019-07-012021-06-30Patients readmitted to any hospital within 30 days of discharge from the inpatient psychiatric facility (READM-30-IPF)No Different than the National Rate20017.914.122.52019-07-012021-06-30Influenza immunization (IPFQR-IMM-2)773392021-10-012022-03-31Percentage of healthcare personnel who completed COVID-19 primary vaccination series (IPFQR-HCP COVID-19)94.1295.02022-07-012022-09-30
10034COMMUNITY HOSPITAL INC805 FRIENDSHIP ROADTALLASSEEAL36078ELMOREHours of physical-restraint use0.00.01385Hours of seclusion use0.00.01385Patients discharged on multiple antipsychotic medications with appropriate justification1.0Screening for metabolic disorders (SMD)10078Alcohol use brief intervention provided or offered1.01.0Alcohol and other drug use disorder treatment provided or offered at discharge1.01.0Tobacco use treatment provided or offered1.01.0Tobacco use treatment provided or offered at discharge1.01.0Transition record with specified elements received by discharged patients (TR1)7893Timely transmission of transition record (TR2)78932021-01-012021-12-31Percent of patients receiving follow-up care within 30 days (FUH-30) or within 7 days (FUH-7) after hospitalization for mental illness1.01.02020-07-012021-06-30Medication Continuation Following Inpatient Psychiatric Discharge1.02019-07-012021-06-30Patients readmitted to any hospital within 30 days of discharge from the inpatient psychiatric facility (READM-30-IPF)No Different than the National Rate4918.013.024.82019-07-012021-06-30Influenza immunization (IPFQR-IMM-2)87452021-10-012022-03-31Percentage of healthcare personnel who completed COVID-19 primary vaccination series (IPFQR-HCP COVID-19)86.652.02022-07-012022-09-30
10039HUNTSVILLE HOSPITAL101 SIVLEY RDHUNTSVILLEAL35801MADISONHours of physical-restraint use0.00.07917Hours of seclusion use0.00.07917Patients discharged on multiple antipsychotic medications with appropriate justification84.057.0Screening for metabolic disorders (SMD)91383Alcohol use brief intervention provided or offered100.097.084.097.0Alcohol and other drug use disorder treatment provided or offered at discharge32.0159.026.0159.0Tobacco use treatment provided or offered100.0306.036.0305.0Tobacco use treatment provided or offered at discharge39.0255.01.0255.0Transition record with specified elements received by discharged patients (TR1)93685Timely transmission of transition record (TR2)916852021-01-012021-12-31Percent of patients receiving follow-up care within 30 days (FUH-30) or within 7 days (FUH-7) after hospitalization for mental illness38.3107.014.0107.02020-07-012021-06-30Medication Continuation Following Inpatient Psychiatric Discharge64.9134.02019-07-012021-06-30Patients readmitted to any hospital within 30 days of discharge from the inpatient psychiatric facility (READM-30-IPF)No Different than the National Rate29521.718.026.02019-07-012021-06-30Influenza immunization (IPFQR-IMM-2)903412021-10-012022-03-31Percentage of healthcare personnel who completed COVID-19 primary vaccination series (IPFQR-HCP COVID-19)89.370.02022-07-012022-09-30